{"transactions":[{"id":733339,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-17T20:05:22.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001631486-26-000008","document":"form4-06172026_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000008/form4-06172026_040614.xml","form_type":"4"}},{"id":733338,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:05:22.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":15960,"source":{"system":"sec-edgar","filing":"0001631486-26-000008","document":"form4-06172026_040614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000008/form4-06172026_040614.xml","form_type":"4"}},{"id":737414,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-15T21:00:35.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."}],"balance_after":15000,"derivative":{"exercise_price":7.3,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-26-000824","document":"e665579_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380526000824/e665579_4-marquet.xml","form_type":"4"}},{"id":739154,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:08:22.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001631486-26-000007","document":"form4a-06122026_080618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000007/form4a-06122026_080618.xml","form_type":"4/A","original_submission_date":"2026-05-14"}},{"id":739153,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-12T20:08:22.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":2500,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001631486-26-000007","document":"form4a-06122026_080618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000007/form4a-06122026_080618.xml","form_type":"4/A","original_submission_date":"2026-05-14"}},{"id":758410,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:05:23.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":8.78,"expiration_date":"2036-05-22","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-26-026427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315226026427/ownership.xml","form_type":"4"}},{"id":758409,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T21:05:23.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 6,250 restricted stock units (\"RSUs\") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the \"2027 Annual Meeting\") is held, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":52342,"source":{"system":"sec-edgar","filing":"0001493152-26-026427","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315226026427/ownership.xml","form_type":"4"}},{"id":778644,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T20:05:22.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms."}],"balance_after":42000,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001631486-26-000006","document":"form4-05142026_040513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000006/form4-05142026_040513.xml","form_type":"4"}},{"id":778643,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-14T20:05:22.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001631486-26-000006","document":"form4-05142026_040513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000006/form4-05142026_040513.xml","form_type":"4"}},{"id":802522,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802521,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802520,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5500,"derivative":{"exercise_price":11.75,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802519,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":3.97,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802518,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":5.67,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802517,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":10600,"derivative":{"exercise_price":6.22,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802516,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":9200,"derivative":{"exercise_price":8.14,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802515,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":7.95,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":802514,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":784,"derivative":{"exercise_price":6.99,"expiration_date":"2031-01-17","underlying":"Common Stock","underlying_shares":784},"source":{"system":"sec-edgar","filing":"0001631486-26-000005","document":"form4-04222026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000163148626000005/form4-04222026_040407.xml","form_type":"4"}},{"id":937025,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-16T18:05:05.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms."}],"balance_after":0,"derivative":{"exercise_price":26.11,"expiration_date":"2031-01-17","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001631486-26-000002","document":"form4-01162026_010101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000163148626000002/form4-01162026_010101.xml","form_type":"4"}},{"id":937024,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T18:05:05.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":1710,"price":48.849,"value":83531.79,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9930,"source":{"system":"sec-edgar","filing":"0001631486-26-000002","document":"form4-01162026_010101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000163148626000002/form4-01162026_010101.xml","form_type":"4"}},{"id":937023,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T18:05:05.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":9290,"price":48.1162,"value":446999.498,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":11640,"source":{"system":"sec-edgar","filing":"0001631486-26-000002","document":"form4-01162026_010101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000163148626000002/form4-01162026_010101.xml","form_type":"4"}},{"id":937022,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T18:05:05.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":true,"shares":11000,"price":26.11,"value":287210.0,"ownership":{"direct":true},"balance_after":20930,"source":{"system":"sec-edgar","filing":"0001631486-26-000002","document":"form4-01162026_010101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000163148626000002/form4-01162026_010101.xml","form_type":"4"}},{"id":943080,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-01-08T21:05:47.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001631486-26-000001","document":"form4-01082026_090143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000163148626000001/form4-01082026_090143.xml","form_type":"4"}},{"id":943079,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T21:05:47.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5500,"derivative":{"exercise_price":43.91,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001631486-26-000001","document":"form4-01082026_090143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000163148626000001/form4-01082026_090143.xml","form_type":"4"}},{"id":1103439,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T20:57:36.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":33000,"derivative":{"exercise_price":2.24,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001641172-25-016113","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000164117225016113/ownership.xml","form_type":"4"}},{"id":1107619,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-17T22:32:21.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001415889-25-017590","document":"form4-06172025_100617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000141588925017590/form4-06172025_100617.xml","form_type":"4"}},{"id":1107618,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:32:21.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":9930,"source":{"system":"sec-edgar","filing":"0001415889-25-017590","document":"form4-06172025_100617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000141588925017590/form4-06172025_100617.xml","form_type":"4"}},{"id":1114564,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-12T00:01:31.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."}],"balance_after":15000,"derivative":{"exercise_price":12.54,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-25-000876","document":"e664622_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380525000876/e664622_4-marquet.xml","form_type":"4"}},{"id":1307649,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:30:18.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001415889-25-001039","document":"form4-01072025_100114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000141588925001039/form4-01072025_100114.xml","form_type":"4"}},{"id":1307648,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T22:30:18.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16510,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001415889-25-001039","document":"form4-01072025_100114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000141588925001039/form4-01072025_100114.xml","form_type":"4"}},{"id":1471692,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T21:45:17.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":33000,"derivative":{"exercise_price":2.04,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001493152-24-024825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315224024825/ownership.xml","form_type":"4"}},{"id":1474574,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-06-19T01:00:43.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."}],"balance_after":15000,"derivative":{"exercise_price":31,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-24-000826","document":"e663727_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380524000826/e663727_4-marquet.xml","form_type":"4"}},{"id":1474573,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2024-06-19T01:00:43.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":false,"shares":3131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3131},"source":{"system":"sec-edgar","filing":"0001193805-24-000826","document":"e663727_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380524000826/e663727_4-marquet.xml","form_type":"4"}},{"id":1474572,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-19T01:00:43.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":true,"shares":3131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024."}],"balance_after":3131,"source":{"system":"sec-edgar","filing":"0001193805-24-000826","document":"e663727_4-marquet.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380524000826/e663727_4-marquet.xml","form_type":"4"}},{"id":1474783,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-06-19T00:17:43.000Z","date":"2024-06-15","kind":"exercise","planned":false,"acquired":false,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001415889-24-017511","document":"form4-06192024_120639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000141588924017511/form4-06192024_120639.xml","form_type":"4"}},{"id":1474782,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-19T00:17:43.000Z","date":"2024-06-15","kind":"exercise","planned":false,"acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":3900,"source":{"system":"sec-edgar","filing":"0001415889-24-017511","document":"form4-06192024_120639.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000141588924017511/form4-06192024_120639.xml","form_type":"4"}},{"id":1474571,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T20:16:51.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-24-072826","document":"tm2417512-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000110465924072826/tm2417512-4_4seq1.xml","form_type":"4"}},{"id":1508490,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T21:25:42.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":21155,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity."}],"balance_after":46092,"source":{"system":"sec-edgar","filing":"0001493152-24-020781","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315224020781/ownership.xml","form_type":"4"}},{"id":1508489,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T21:25:42.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":25002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted Stock Awards which will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":25002,"source":{"system":"sec-edgar","filing":"0001493152-24-020781","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315224020781/ownership.xml","form_type":"4"}},{"id":1685261,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-01-05T21:59:07.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001209191-24-001051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919124001051/doc4.xml","form_type":"4"}},{"id":1685260,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:59:07.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16510,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001209191-24-001051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919124001051/doc4.xml","form_type":"4"}},{"id":1784459,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T21:46:34.000Z","date":"2023-09-06","kind":"purchase","planned":false,"acquired":true,"shares":9000,"price":2.4681,"value":22212.9,"ownership":{"direct":false,"nature":"Via ALMA Life Sciences, LLC"},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001493152-23-032150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315223032150/ownership.xml","form_type":"4"}},{"id":1786654,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T20:33:08.000Z","date":"2023-09-05","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.4722,"value":24722.0,"ownership":{"direct":false,"nature":"Via ALMA Life Sciences, LLC"},"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001493152-23-031838","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315223031838/ownership.xml","form_type":"4"}},{"id":1788735,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-05T22:43:17.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":2.01,"value":2010.0,"ownership":{"direct":false,"nature":"Via ALMA Life Sciences, LLC"},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001493152-23-031708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315223031708/ownership.xml","form_type":"4"}},{"id":1808171,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-08-14T20:15:28.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest monthly over 12 months from the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":1.86,"expiration_date":"2033-08-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-23-028469","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315223028469/ownership.xml","form_type":"4"}},{"id":1815820,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2023-08-03T20:09:32.000Z","date":"2023-08-01","kind":"grant","planned":false,"acquired":true,"shares":3131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit is economically equivalent to one share of the Issuer's common stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."}],"balance_after":3131,"derivative":{"underlying":"Common Stock","underlying_shares":3131},"source":{"system":"sec-edgar","filing":"0001193805-23-001069","document":"e618807_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380523001069/e618807_4-marquet.xml","form_type":"4"}},{"id":1815819,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-08-03T20:09:32.000Z","date":"2023-08-01","kind":"grant","planned":false,"acquired":true,"shares":11869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer."}],"balance_after":11869,"derivative":{"exercise_price":34.92,"expiration_date":"2033-08-01","underlying":"Common Stock","underlying_shares":11869},"source":{"system":"sec-edgar","filing":"0001193805-23-001069","document":"e618807_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380523001069/e618807_4-marquet.xml","form_type":"4"}},{"id":1884035,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-20T00:08:18.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time."}],"balance_after":45000,"derivative":{"exercise_price":0.2834,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-23-062815","document":"tm2316383-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000110465923062815/tm2316383-5_4seq1.xml","form_type":"4"}},{"id":1897821,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-10T22:12:05.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 10, 2024 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":9500,"derivative":{"exercise_price":0.2985,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001104659-23-058581","document":"tm2315294-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000110465923058581/tm2315294-2_4seq1.xml","form_type":"4"}},{"id":2057350,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-01-11T00:09:06.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":3900,"derivative":{"underlying":"Common Stock","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001209191-23-002882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919123002882/doc4.xml","form_type":"4"}},{"id":2057349,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-11T00:09:06.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":10600,"derivative":{"exercise_price":23.23,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001209191-23-002882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919123002882/doc4.xml","form_type":"4"}},{"id":2081068,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-19T22:02:13.000Z","date":"2022-12-15","kind":"purchase","acquired":true,"shares":2222,"price":18,"value":39996.0,"ownership":{"direct":false,"nature":"Via Alma Life Sciences, LLC"},"balance_after":24942,"source":{"system":"sec-edgar","filing":"0001193805-22-001748","document":"e618133_4-marquet.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380522001748/e618133_4-marquet.xml","form_type":"4"}},{"id":2206156,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-07-18T10:10:16.000Z","date":"2022-07-14","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest monthly over 12 months from date of grant."}],"balance_after":76000,"derivative":{"exercise_price":2.64,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001493152-22-019512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000149315222019512/ownership.xml","form_type":"4"}},{"id":2220862,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T23:16:25.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors."}],"balance_after":15000,"derivative":{"exercise_price":16.02,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-22-001023","document":"e621784_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380522001023/e621784_4-marquet.xml","form_type":"4"}},{"id":2223726,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-23T00:25:59.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":9500,"derivative":{"exercise_price":1.24,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001104659-22-073635","document":"tm2219203-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000110465922073635/tm2219203-2_4seq1.xml","form_type":"4"}},{"id":2397367,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-14T21:54:24.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":9200,"derivative":{"exercise_price":30.44,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001209191-22-009361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919122009361/doc4.xml","form_type":"4"}},{"id":2658228,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T22:32:16.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors."}],"balance_after":15000,"derivative":{"exercise_price":35.09,"expiration_date":"2031-06-18","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-21-000928","document":"e620748_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380521000928/e620748_4-marquet.xml","form_type":"4"}},{"id":2862650,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-13T02:40:46.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":11000,"derivative":{"exercise_price":29.7,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-21-010531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919121010531/doc4.xml","form_type":"4"}},{"id":2904003,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-19T21:36:48.000Z","date":"2021-01-18","kind":"grant","acquired":true,"shares":784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall be fully vested as of February 12, 2021, subject to the Reporting Person's continued service on the vesting date."}],"balance_after":784,"derivative":{"exercise_price":26.11,"expiration_date":"2031-01-17","underlying":"Common Stock","underlying_shares":784},"source":{"system":"sec-edgar","filing":"0001209191-21-004027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919121004027/doc4.xml","form_type":"4"}},{"id":2904002,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-19T21:36:48.000Z","date":"2021-01-18","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning on February 18, 2021 until fully vested, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":11000,"derivative":{"exercise_price":26.11,"expiration_date":"2031-01-17","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-21-004027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919121004027/doc4.xml","form_type":"4"}},{"id":3013168,"issuer":{"id":146052,"kind":"organization","name":"Pfenex Inc.","symbol":"PFNX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-05T20:36:59.000Z","date":"2020-10-01","kind":"other","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the \"Option Consideration\"). All Option Consideration will be paid without interest and less any applicable tax withholdings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the \"Annual Meeting\") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan)."}],"balance_after":0,"derivative":{"exercise_price":6.43,"expiration_date":"2030-05-08","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-20-027425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478121/000089924320027425/doc4.xml","form_type":"4"}},{"id":3013167,"issuer":{"id":146052,"kind":"organization","name":"Pfenex Inc.","symbol":"PFNX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-05T20:36:59.000Z","date":"2020-10-01","kind":"other","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the \"Option Consideration\"). All Option Consideration will be paid without interest and less any applicable tax withholdings."}],"balance_after":0,"derivative":{"exercise_price":4.49,"exercise_date":"2020-05-08","expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-20-027425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478121/000089924320027425/doc4.xml","form_type":"4"}},{"id":3100669,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T00:01:39.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares underlying the options vest monthly over a one year period from the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":40.7,"expiration_date":"2030-06-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-20-000745","document":"e619724_4-marquet.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000119380520000745/e619724_4-marquet.xml","form_type":"4"}},{"id":3154357,"issuer":{"id":146052,"kind":"organization","name":"Pfenex Inc.","symbol":"PFNX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-11T20:11:15.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the \"Annual Meeting\") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan)."}],"balance_after":18000,"derivative":{"exercise_price":6.43,"expiration_date":"2030-05-08","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-20-012692","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478121/000089924320012692/doc4.xml","form_type":"4"}},{"id":3386082,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-30T00:12:22.000Z","date":"2019-10-25","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares underlying the options vest monthly over a one year period from the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":10.23,"expiration_date":"2029-10-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-026116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000089924319026116/doc4.xml","form_type":"4"}},{"id":3411754,"issuer":{"id":5523,"kind":"organization","name":"Arcturus Therapeutics Holdings Inc."},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-18T01:37:12.000Z","date":"2019-09-13","kind":"purchase","acquired":true,"shares":2300,"price":10.58,"value":24334.0,"ownership":{"direct":false,"nature":"Via Alma Life Sciences, LLC"},"balance_after":22720,"source":{"system":"sec-edgar","filing":"0000899243-19-023769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631486/000089924319023769/doc4.xml","form_type":"4"}},{"id":3618912,"issuer":{"id":146052,"kind":"organization","name":"Pfenex Inc.","symbol":"PFNX"},"owners":[{"id":37128,"kind":"person","name":"Marquet Magda","position":1,"cik":"0001631486","reported_name":"Marquet Magda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-04T19:37:19.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the \"Annual Meeting\") held after February 28, 2019, subject to the reporting person's continuing service through the date of the Annual Meeting."}],"balance_after":25000,"derivative":{"exercise_price":4.49,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-005932","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478121/000089924319005932/doc4.xml","form_type":"4"}}]}